Spots Global Cancer Trial Database for Peri-operative Chemotherapy With ECX or XP in the Treatment of Advanced Gastric Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Peri-operative Chemotherapy With ECX or XP in the Treatment of Advanced Gastric Cancer
Official Title: Peri-operative Chemotherapy With ECX (Epirubicin + Cisplatin + Capecitabine) or XP (Capecitabine + Cisplatin) in the Treatment of Advanced Gastric Cancer: a Randomized, Multicenter, Parallel Control
Study ID: NCT01558947
Conditions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety and the effect of perioperative chemotherapy in the treatment of advanced gastric cancer.
Detailed Description: To evaluate the security and the relapse-free survival time/rate(1,2,3 yrs) of perioperative chemotherapy with ECX (epirubicin + cisplatin + capecitabine) and XP (capecitabine + cisplatin）in advanced gastric cancer
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Contact Details
Name: xiangdong Cheng, MD
Affiliation: Zhejiang Cancer Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
